Protocols
17 protocol(s) meet the specified criteria
Disease Site: Lip, Oral Cavity and Pharynx
Protocol No.TitleStatus
12-040-EClinical Registry of Dental Outcomes in Head and Neck Cancer Patients (ORARAD) Open
B8011001A Phase 1, Open-Label, Dose Escalation and Expansion Study of PF-06801591 in Patients with Locally Advanced or Metastatic Melanoma, Squamous Cell Head and Neck Cancer, Ovarian Cancer, Sarcoma, or Relapsed or Refractory Classic Hodgkin Lymphoma or Other Solid TumorsOpen
D419LC00001A Phase III Randomized, Open-label, Multi-center, Global Study of MEDI4736 Alone or in Combination with Tremelimumab versus Standard of Care in the Treatment of First-line Recurrent or Metastatic Squamous Cell Head and Neck Cancer PatientsOpen
LCCC1330A Phase II study of carboplatin, paclitaxel and cetuximab for patients with recurrent or metastatic squamous cell carcinoma of the head and neckOpen
LCCC1413De-intensification of Radiation and Chemotherapy for Favorable-Risk HPV-related Oropharyngeal Squamous Cell CarcinomaOpen
LCCC1430Phase Ib trial of Dose-escalating AZD1775 in Combination with Concurrent Radiation and Cisplatin for Intermediate and High Risk Head and Neck Squamous Cell Carcinoma (HNSCC)Open
LCCC1509Pembrolizumab and Radiation for Locally Advanced Squamous Cell Carcinoma of the Head and Neck (SCCHN) not Eligible for Cisplatin TherapyOpen
LCCC1538Geriatric Assessment Reporting in Real Time (GARRT) in non-electively hospitalized older cancer patients: feasibility, impact, and clinician acceptance.Open
LCCC1601Symptom management needs of patients treated for head and neck cancerOpen
LCCC1608HIV and other Risk Factors for Esophageal Squamous Cell Carcinoma in MalawiOpen
LCCC1612P53 mutational status and circulating free HPV DNA for the management of HPV-associated Oropharyngeal Squamous Cell Cancers Open
MCC-16962A Phase I Trial of Dose Escalation of Metformin in Combination with Vincristine, Irinotecan, and Temozolomide in Children with Relapsed or Refractory Solid TumorsOpen
ML28897PRO/02My Pathway: An Open-Label Phase IIA Study Evaluating Trastuzumab/Pertuzumab, Erlotinib, Vemurafenib/Cobimetinib, and Vismodegib in Patients who have Advanced Solid Tumors with Mutations or Gene Expression Abnormalities Predictive of Response to one of these Agents.Open
MM-398-01-01-02A Phase 1 Study in Patients Treated with MM-398 (Nanoliposomal Irinotecan, nal-IRI,) to Determine Tumor Drug Levels and to Evaluate the Feasibility of Ferumoxytol Magnetic Resonance Imaging to Measure Tumor Associated Macrophages and to Predict Patient Response to TreatmentOpen
PCRC-14-07Caregiver-­‐guided pain management training in palliative careOpen
RTOG1008A Randomized Phase II/III Study of Adjuvant Concurrent Radiation and Chemotherapy versus Radiation Alone in Resected High-Risk Malignant Salivary Gland Tumors Open
TRT-001A Multi-center Study of hTERT Immunotherapy Alone or in Combination with IL-12 DNA Followed by Electroporation in Adults with Solid Tumors at High Risk of Relapse Post Definitive Surgery and Standard TherapyOpen